GENE ONLINE|News &
Opinion
Blog

2019-12-31| M&A

Astellas Procures Xyphos Biosciences as Second Acquisition in December

by Sherry
Share To

By Rajaneesh K. Gopinath, Ph.D.

Astellas Pharma Inc., the second-largest pharmaceutical company in Japan, acquired the American gene therapy development company Audentes Therapeutics for $3 billion in early December 2019. At the end of December, it announced the acquisition of Xyphos Biosciences in South San Francisco to accelerate the next generation of cancer immunotherapy products. Xyphos will become a wholly-owned subsidiary of Astellas with a total acquisition value of $665 million.

With this acquisition, Astellas will get Xyphos’ new ACCEL (Advanced Cellular Control through engineered Ligands) technology platform, which can guide the cells of the immune system to target single or multiple tumor antigens, while controlling the proliferation and persistence of immune cells. Xyphos’ proprietary molecules can be delivered to natural immune cells or to engineered Chimeric Antigen Receptor (CAR) cells to generate immunotherapies for oncology. Xyphos’ first CAR-T cell candidate is currently undergoing preclinical development, with the first clinical trial planned for 2021.

Astellas’ two acquisitions at the end of 2019 merged two San Francisco biotech companies for a total of US $5.2 billion to strengthen its product development in cancer immunotherapy and gene therapy. The two acquisitions not only boosted the share price of US-related gene therapy and cancer immunotherapy companies but also increased the activity of mergers and acquisitions of biotech companies in San Francisco. It kicked off the upcoming J.P. Morgan 38th Annual Healthcare Conference in San Francisco.

 

References

  1. https://newsroom.astellas.us/2019-12-26-Astellas-Strengthens-Immuno-oncology-Pipeline-with-Acquisition-of-Xyphos-Biosciences-Inc

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Astellas’ Claudin 18.2 Antibody Shows Its Teeth In GEJ Cancer Trial
2022-11-17
Astellas Invests $50 Million In Taysha, Licenses Two CNS Gene Therapies
2022-10-25
Kite to Use Refuge’s Gene Expression Platform for New CAR-T Therapies
2022-10-21
LATEST
Targeting Metabolism for Noninvasive Multi-Cancer Early Detection Tests
2022-12-08
Moderna’s Personalized Cancer Therapy: The New Transformative Approach to Oncology
2022-12-08
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
2022-12-08
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!